CA2997784A1 - Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents - Google Patents

Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents Download PDF

Info

Publication number
CA2997784A1
CA2997784A1 CA2997784A CA2997784A CA2997784A1 CA 2997784 A1 CA2997784 A1 CA 2997784A1 CA 2997784 A CA2997784 A CA 2997784A CA 2997784 A CA2997784 A CA 2997784A CA 2997784 A1 CA2997784 A1 CA 2997784A1
Authority
CA
Canada
Prior art keywords
mmol
compound according
pyran
alkyl
phenoxazin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2997784A
Other languages
English (en)
French (fr)
Inventor
Michael Ohlmeyer
Nilesh ZAWARE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icahn School of Medicine at Mount Sinai
Original Assignee
Icahn School of Medicine at Mount Sinai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icahn School of Medicine at Mount Sinai filed Critical Icahn School of Medicine at Mount Sinai
Publication of CA2997784A1 publication Critical patent/CA2997784A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA2997784A 2015-09-09 2016-09-08 Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents Abandoned CA2997784A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562216172P 2015-09-09 2015-09-09
US62/216,172 2015-09-09
PCT/US2016/050688 WO2017044569A1 (en) 2015-09-09 2016-09-08 Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents

Publications (1)

Publication Number Publication Date
CA2997784A1 true CA2997784A1 (en) 2017-03-16

Family

ID=56936551

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2997784A Abandoned CA2997784A1 (en) 2015-09-09 2016-09-08 Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents

Country Status (8)

Country Link
US (1) US10759790B2 (https=)
EP (1) EP3347355B1 (https=)
JP (1) JP6955485B2 (https=)
CN (1) CN108349961B (https=)
AR (1) AR105975A1 (https=)
CA (1) CA2997784A1 (https=)
TW (1) TW201808930A (https=)
WO (1) WO2017044569A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015138500A1 (en) 2014-03-11 2015-09-17 Icahn School Of Medicine At Mount Sinai Sulfonamides derived from tricyclyl-2-aminocycloalkanols as anticancer agents
WO2015138496A1 (en) 2014-03-11 2015-09-17 Icahn School Of Medicine At Mount Sinai Constrained tricyclic sulfonamides
WO2017024229A1 (en) * 2015-08-06 2017-02-09 Icahn School Of Medecine At Mount Sinai Stereospecific process for 3-heterocyclylcycloaliphatic-1,2-diols
CA2997769A1 (en) 2015-09-09 2017-03-16 Icahn School Of Medicine At Mount Sinai Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents
WO2021150697A1 (en) * 2020-01-22 2021-07-29 Icahn School Of Medicine At Mount Sinai N-substituted-3-tricyclyl piperidine derivatives as anticancer and neuroprotective agents
WO2021150700A1 (en) * 2020-01-22 2021-07-29 Icahn School Of Medicine At Mount Sinai N-substituted-3-tricyclyl piperidine derivatives as anticancer and neuroprotective agents
CN112778257A (zh) * 2021-01-21 2021-05-11 香港科技大学 一种将糠醇氧化为二氢吡喃酮类衍生物的绿色方法
CN116806217A (zh) * 2021-02-08 2023-09-26 拉帕塔疗法公司 蛋白磷酸酶2a(pp2a)的取代的环状调节剂及其使用方法
AU2022216880A1 (en) * 2021-02-08 2023-08-10 Rappta Therapeutics Oy Substituted cyclic modulators of protein phosphatase 2a (pp2a) and methods using same
WO2023245297A1 (en) * 2022-06-23 2023-12-28 University Of Ottawa Ferroptosis inhibitors and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634766A (en) 1983-10-31 1987-01-06 Merck Frosst Canada, Inc. 1,4-diaza-phenothiazines
GB8510680D0 (en) 1985-04-26 1985-06-05 Smith Kline French Lab Pyridine derivatives
US4882351A (en) 1987-10-14 1989-11-21 Roussel Uclaf Tricyclic compounds
US5834462A (en) 1993-07-26 1998-11-10 Eisai Co., Ltd. Tricyclic heterocyclic sulfonamide and sulfonic ester derivatives
WO1997030038A1 (en) 1996-02-15 1997-08-21 Mitsubishi Chemical Corporation Diarylsultam derivatives
US6333322B1 (en) 1996-03-13 2001-12-25 Eisai Co., Ltd. Nitrogen-containing tricyclic compounds and drugs containing the same
AU2641899A (en) 1998-02-27 1999-09-15 Eisai Co. Ltd. Heterocycle-fused benzothiazine derivatives
WO2002024657A2 (en) 2000-09-20 2002-03-28 Schering Corporation Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists
WO2003066040A1 (en) 2002-02-05 2003-08-14 Ajinomoto Co.,Inc. Medicinal compositions containing gabapentin or pregabalin and n-type calcium channel antagonist
TW200400816A (en) 2002-06-26 2004-01-16 Lilly Co Eli Tricyclic steroid hormone nuclear receptor modulators
EP1838690A2 (en) 2004-12-21 2007-10-03 Devgen N.V. Compounds with kv4 ion channel activity
IT1362675B (it) 2005-03-15 2009-06-25 Menarini Internat Operations Luxembourg Sa N-idrossiammidi -sostituiti con gruppi triciclici come inibitori dell'istone deacelitasi,loro preparazione ed impiego in formulazioni farmaceutiche
AU2006239929B2 (en) 2005-04-22 2011-11-03 Alantos Pharmaceuticals Holding, Inc. Dipeptidyl peptidase-IV inhibitors
GB0508992D0 (en) 2005-05-03 2005-06-08 Novartis Ag Organic compounds
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
WO2008121859A1 (en) 2007-03-30 2008-10-09 Xenon Pharmaceuticals Inc. Methods of using tricyclic compounds in treating sodium channel-mediated diseases or conditions
EP2705036B1 (en) * 2011-05-06 2015-08-12 Zafgen Inc. Tricyclic sulfonamide compounds and methods of making and using same
HK1198384A1 (en) * 2011-08-16 2015-04-17 Mt. Sinai School Of Medicine Tricyclic compounds as anticancer agents
AU2013305591B2 (en) 2012-08-24 2017-04-13 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
CN102942562B (zh) 2012-12-05 2014-10-01 天津市斯芬克司药物研发有限公司 一种苯并咪唑衍生物及其制备方法和应用
BR112015019818A2 (pt) 2013-02-19 2017-07-18 Icahn School Med Mount Sinai composto, uso de um composto, e, composição farmacêutica
WO2015138500A1 (en) * 2014-03-11 2015-09-17 Icahn School Of Medicine At Mount Sinai Sulfonamides derived from tricyclyl-2-aminocycloalkanols as anticancer agents
WO2015138496A1 (en) 2014-03-11 2015-09-17 Icahn School Of Medicine At Mount Sinai Constrained tricyclic sulfonamides
WO2017024229A1 (en) 2015-08-06 2017-02-09 Icahn School Of Medecine At Mount Sinai Stereospecific process for 3-heterocyclylcycloaliphatic-1,2-diols
WO2017044571A1 (en) 2015-09-09 2017-03-16 Icahn School Of Medicine At Mount Sinai Tricyclic sultam sulfonamides as anticancer and neuroprotective agents
WO2017044572A1 (en) 2015-09-09 2017-03-16 Icahn School Of Medicine At Mount Sinai Ring constrained diarylamino sulfonamides as anti-cancer agents
CA2997769A1 (en) 2015-09-09 2017-03-16 Icahn School Of Medicine At Mount Sinai Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents
WO2017044575A1 (en) 2015-09-09 2017-03-16 Icahn School Of Medicine At Mount Sinai Constrained benzhydryl sulfonamides as anticancer and neuroprotective agents

Also Published As

Publication number Publication date
JP6955485B2 (ja) 2021-10-27
WO2017044569A1 (en) 2017-03-16
TW201808930A (zh) 2018-03-16
CN108349961B (zh) 2022-02-18
EP3347355B1 (en) 2022-07-13
HK1259348A1 (zh) 2019-11-29
AR105975A1 (es) 2017-11-29
JP2018526419A (ja) 2018-09-13
US20180251456A1 (en) 2018-09-06
CN108349961A (zh) 2018-07-31
US10759790B2 (en) 2020-09-01
EP3347355A1 (en) 2018-07-18

Similar Documents

Publication Publication Date Title
CA2997784A1 (en) Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents
AU2021237841B2 (en) Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
CA2963832C (en) Methods for treating filoviridae virus infections
CN103003233B (zh) 新型异羟肟酸衍生物
CA3082212C (en) Bruton's tyrosine kinase inhibitors
CA3215395A1 (en) Compounds, compositions and methods of treating cancer
EP3116860B1 (en) Sulfonamides derived from tricyclyl-2-aminocycloalkanols as anticancer agents
US10221158B2 (en) Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents
JP2020532506A (ja) 化合物、組成物、及び、方法
AU2018291688B2 (en) Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections
WO2017044575A1 (en) Constrained benzhydryl sulfonamides as anticancer and neuroprotective agents
TWI438202B (zh) 作為抗病毒劑追加劑之醯胺化合物
CA3190495A1 (en) Compounds, compositions and methods
TW201827437A (zh) 作為hiv整合酶抑制劑之四環雜環化合物
WO2017044571A1 (en) Tricyclic sultam sulfonamides as anticancer and neuroprotective agents
CA2902764A1 (en) Ship1 modulators and methods related thereto
CN116528869A (zh) 氨基杂芳基激酶抑制剂
WO2024056019A1 (en) Bicyclic compounds as cdk inhibitors
CA2808590A1 (en) Sulfonylpiperazine derivatives that interact with glucokinase regulatory protein for the treatment of diabetes
CA2815055A1 (en) Viral polymerase inhibitors
EP4405344A2 (en) Pyridinyl derivatives as sodium channel activators
HK1259348B (en) Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210817

FZDE Discontinued

Effective date: 20240206